These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


121 related items for PubMed ID: 3344715

  • 1. A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study.
    Maurer HS, Lloyd-Still JD, Ingrisano C, Gonzalez-Crussi F, Honig GR.
    Am J Dis Child; 1988 Mar; 142(3):287-92. PubMed ID: 3344715
    [Abstract] [Full Text] [Related]

  • 2. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
    Cossu P, Toccafondi C, Vardeu F, Sanna G, Frau F, Lobrano R, Cornacchia G, Nucaro A, Bertolino F, Loi A, De Virgiliis S, Cao A.
    Eur J Pediatr; 1981 Nov; 137(3):267-71. PubMed ID: 7318837
    [Abstract] [Full Text] [Related]

  • 3. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.
    Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Laulicht M, Fenton LA, Scheuer PJ, Kibbler CC, Allwood CA, Brown D.
    J Clin Pathol; 1987 Nov; 40(11):1353-9. PubMed ID: 3121679
    [Abstract] [Full Text] [Related]

  • 4. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation.
    Muretto P, Angelucci E, Lucarelli G.
    Ann Intern Med; 2002 May 07; 136(9):667-72. PubMed ID: 11992302
    [Abstract] [Full Text] [Related]

  • 5. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A.
    Ann Hematol; 2008 Jul 07; 87(7):545-50. PubMed ID: 18351337
    [Abstract] [Full Text] [Related]

  • 6. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA.
    N Engl J Med; 1998 Aug 13; 339(7):417-23. PubMed ID: 9700174
    [Abstract] [Full Text] [Related]

  • 7. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A, Imbach P, Pfenninger E, Stocker F, Töndury P, Wagner HP, Weber J, Zuppinger K.
    Helv Paediatr Acta; 1985 Sep 13; 40(4):293-304. PubMed ID: 4077563
    [Abstract] [Full Text] [Related]

  • 8. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.
    Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW.
    J Pediatr; 1991 Apr 13; 118(4 Pt 1):540-5. PubMed ID: 2007928
    [Abstract] [Full Text] [Related]

  • 9. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress.
    Barry M, Flynn DM, Letsky EA, Risdon RA.
    Br Med J; 1974 Apr 06; 2(5909):16-20. PubMed ID: 4821036
    [Abstract] [Full Text] [Related]

  • 10. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Apr 06; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 11. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
    De Virgiliis S, Cossu P, Sanna G, Frau F, Loi E, Lobrano R, Nucaro A, Toccafondi C, Cornacchia G, Loi A, Cao A.
    Acta Haematol; 1982 Apr 06; 67(1):49-56. PubMed ID: 6800202
    [Abstract] [Full Text] [Related]

  • 12. Sustained normalization of cardiac function by chelation therapy in thalassaemia major.
    Freeman AP, Giles RW, Berdoukas VA, Talley PA, Murray IP.
    Clin Lab Haematol; 1989 Apr 06; 11(4):299-307. PubMed ID: 2605872
    [Abstract] [Full Text] [Related]

  • 13. Depletion of excessive liver iron stores with desferrioxamine.
    Cohen A, Martin M, Schwartz E.
    Br J Haematol; 1984 Oct 06; 58(2):369-73. PubMed ID: 6477838
    [Abstract] [Full Text] [Related]

  • 14. Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia.
    Risdon RA, Barry M, Flynn DM.
    J Pathol; 1975 Jun 06; 116(2):83-95. PubMed ID: 1151528
    [Abstract] [Full Text] [Related]

  • 15. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF, Peng CT, Wu KH, Tsai CH.
    Hemoglobin; 2006 Jun 06; 30(2):215-8. PubMed ID: 16798646
    [Abstract] [Full Text] [Related]

  • 16. Early iron overload in beta-thalassaemia major: when to start chelation therapy?
    Fargion S, Taddei MT, Gabutti V, Piga A, Di Palma A, Capra L, Fontanelli G, Avanzini A.
    Arch Dis Child; 1982 Dec 06; 57(12):929-33. PubMed ID: 7181522
    [Abstract] [Full Text] [Related]

  • 17. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Transfusion; 2007 Oct 06; 47(10):1919-29. PubMed ID: 17880620
    [Abstract] [Full Text] [Related]

  • 18. Combined subcutaneous and high-dose intravenous deferoxamine therapy of thalassemia.
    Hyman CB, Agness CL, Rodriguez-Funes R, Zednikova M.
    Ann N Y Acad Sci; 1985 Oct 06; 445():293-303. PubMed ID: 3860133
    [Abstract] [Full Text] [Related]

  • 19. Thalassemia.
    Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E.
    Hematology Am Soc Hematol Educ Program; 2004 Oct 06; ():14-34. PubMed ID: 15561674
    [Abstract] [Full Text] [Related]

  • 20. The effect of desferrioxamine chelation versus no therapy in patients with non transfusion-dependent thalassaemia: a multicenter prospective comparison from the MIOT network.
    Ricchi P, Meloni A, Pistoia L, Spasiano A, Spiga A, Allò M, Gamberini MR, Lisi R, Campisi S, Peluso A, Missere M, Renne S, Mangione M, Positano V, Pepe A.
    Ann Hematol; 2018 Oct 06; 97(10):1925-1932. PubMed ID: 29926157
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.